These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 7697011

  • 1. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
    Gewirtz AM.
    Bone Marrow Transplant; 1994; 14 Suppl 3():S57-61. PubMed ID: 7697011
    [No Abstract] [Full Text] [Related]

  • 2. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P, Calabretta B.
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract] [Full Text] [Related]

  • 3. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 4. Antisense gene therapy trials underway in patients with CML.
    Oncology (Williston Park); 1996 Sep; 10(9):1411. PubMed ID: 8882929
    [No Abstract] [Full Text] [Related]

  • 5. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
    Yuan T, Zhou YQ, Herst CV, Reading C, Ellersen D, Etkin M, Khouri I, Kantarjian H, Talpaz M, Deisseroth A.
    Prog Clin Biol Res; 1992 Sep; 377():227-30. PubMed ID: 1438419
    [No Abstract] [Full Text] [Related]

  • 6. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM.
    Leuk Lymphoma; 1993 Sep; 11 Suppl 1():131-7. PubMed ID: 7504543
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bone marrow purging with antisense oligodeoxynucleotides.
    Gewirtz AM.
    Prog Clin Biol Res; 1992 Sep; 377():215-24; discussion 225-6. PubMed ID: 1438418
    [No Abstract] [Full Text] [Related]

  • 9. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F.
    Blood; 1998 May 01; 91(9):3156-62. PubMed ID: 9558370
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C, Skórski T, Malaguarnera L, Hetman J, Chen ST, Calabretta B.
    Folia Histochem Cytobiol; 1996 May 01; 34(3-4):129-34. PubMed ID: 8967957
    [Abstract] [Full Text] [Related]

  • 11. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P, Amadori S, Calabretta B, Mandelli F.
    Bone Marrow Transplant; 1993 Sep 01; 12(3):261-5. PubMed ID: 8241986
    [Abstract] [Full Text] [Related]

  • 12. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation.
    de Fabritis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F.
    Leukemia; 1995 Apr 01; 9(4):662-4. PubMed ID: 7536864
    [Abstract] [Full Text] [Related]

  • 13. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP.
    Prog Clin Biol Res; 1994 Apr 01; 389():175-82. PubMed ID: 7700900
    [No Abstract] [Full Text] [Related]

  • 14. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM.
    Curr Opin Mol Ther; 1999 Jun 01; 1(3):297-306. PubMed ID: 11713794
    [Abstract] [Full Text] [Related]

  • 15. Myb targeted therapeutics for the treatment of human malignancies.
    Gewirtz AM.
    Oncogene; 1999 May 13; 18(19):3056-62. PubMed ID: 10378701
    [Abstract] [Full Text] [Related]

  • 16. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
    Liu J, Jiang J, Zhang Y, Wu D, Yang G, Huang X, Wei X.
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec 13; 32(4):599-601. PubMed ID: 12528561
    [Abstract] [Full Text] [Related]

  • 17. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
    Etienne G, Mahon FX.
    Bull Cancer; 2001 Jul 13; 88(7):651-8. PubMed ID: 11495816
    [Abstract] [Full Text] [Related]

  • 18. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM.
    Proc Natl Acad Sci U S A; 1992 Dec 15; 89(24):11823-7. PubMed ID: 1281545
    [Abstract] [Full Text] [Related]

  • 19. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G, Tam YK, Berkahn L, Klingemann HG.
    Bone Marrow Transplant; 2003 Jun 15; 31(12):1119-25. PubMed ID: 12796791
    [Abstract] [Full Text] [Related]

  • 20. Chronic myelogenous leukemia--the unfolding saga.
    Goldman JM, Grosveld G, Baltimore D, Gale RP.
    Leukemia; 1990 Mar 15; 4(3):163-7. PubMed ID: 2179637
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.